Skip to main menu Skip to main content Skip to footer


Durability of Encapsulated Cell Therapy (ECT)

Two-year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases
Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P, Dean B, Lee A, Borges S, Bouchard B, Tao W. Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7484-91. doi: 10.1167/iovs.12-9970. PMID: 23049090.

Sustained secretion of Ciliary Neurotrophic Factor to the Vitreous, Using the Encapsulated Cell Therapy-based NT-501 Intraocular Device
Christopher G. Thanos, William J. Bell, P. O’Rourke, Konrad Kauper, Sandy Sherman, Paul Stabila, and Weng Tao. Published Online:28 Dec 2004

Encapsulated Cells as Therapy
Lysaght MJ, Aebischer P.Sci Am. 1999 Apr;280(4):76-82. doi: 10.1038/scientificamerican0499-76.PMID: 10201119 

Encapsulated Cell-based Intraocular Delivery of Ciliary Neurotrophic Factor in Normal Rabbit: Dose-dependent Effects on ERG and Retinal Histology
Ronald A Bush 1, Bo Lei, Weng Tao, Dorit Raz, Chi-Chao Chan, Terry A Cox, Maria Santos-Muffley, Paul A Sieving. PMID: 15223826 DOI: Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2420-30. doi: 10.1167/iovs.03-1342. PMID: 15223826

Continuous Intraocular Drug Delivery Lasting Over a Decade: Ciliary Neurotrophic Factor (CNTF) Secreted from Neurotech’s NT-501 Implanted in Subjects with Retinal Degenerative Disorders
Konrad Kauper; Lisa Orecchio; Arne Nystuen; Kayla Medeiros; Alice Lee; Vanessa Cavallaro; Jacque L Duncan; Thomas Aaberg. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3680.

Neuroprotective Properties of Ciliary Neurotrophic Factor (CNTF)

CNTF and Retina
Wen R, Tao W, Li Y, Sieving PA. Prog Retin Eye Res. 2012 Mar;31(2):136-51. doi: 10.1016/j.preteyeres.2011.11.005. Epub 2011 Dec 10. PMID: 22182585; PMCID: PMC3288688.

Encapsulated Cell-based Delivery of CNTF Reduces Photoreceptor Degeneration in Animal Models of Retinitis Pigmentosa
Tao W, Wen R, Goddard MB, Sherman SD, O’Rourke PJ, Stabila PF, Bell WJ, Dean BJ, Kauper KA, Budz VA, Tsiaras WG, Acland GM, Pearce-Kelling S, Laties AM, Aguirre GD. Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3292-8. PMID: 12356837.

CNTF Induces Dose-dependent Alterations in Retinal Morphology in Normal and rcd-1 Canine Retina
Zeiss CJ, Allore HG, Towle V, Tao W. Exp Eye Res. 2006 Mar;82(3):395-404. doi: 10.1016/j.exer.2005.07.014. Epub 2005 Sep 6. PMID: 16143329.

Application of Encapsulated Cell Technology for Retinal Degenerative Diseases
Tao W. Expert Opin Biol Ther. 2006 Jul;6(7):717-26. doi: 10.1517/14712598.6.7.717. PMID: 16805711.

Regeneration of Cone Outer Segments Induced by CNTF
Wen R, Tao W, Luo L, Huang D, Kauper K, Stabila P, LaVail MM, Laties AM, Li Y. Adv Exp Med Biol. 2012;723:93-9. doi: 10.1007/978-1-4614-0631-0_13. PMID: 22183320; PMCID: PMC3552642.

CNTF Induces Regeneration of Cone Outer Segments in a Rat Model of Retinal Degeneration
Yiwen Li,Weng Tao,Lingyu Luo,Deqiang Huang,Konrad Kauper,Paul Stabila,Matthew M. LaVail,Alan M. Laties,Rong Wen. Published: March 2, 2010.

Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement
Goldberg JL, Beykin G, Satterfield KR, Nuñez M, Lam BL, Albini TA. Ophthalmol Sci. 2023 Mar 11;3(3):100298.